<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Clinical Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0E3923DA-27B7-4AEC-AE5D-72D7034A6771"><gtr:id>0E3923DA-27B7-4AEC-AE5D-72D7034A6771</gtr:id><gtr:firstName>Chen</gtr:firstName><gtr:surname>Bing</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6FE375B7-582A-4E68-B5C2-7BD8E6AC5E95"><gtr:id>6FE375B7-582A-4E68-B5C2-7BD8E6AC5E95</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Trayhurn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE015379%2F1"><gtr:id>F68B4B04-D16B-4020-8712-D3FF49C06B8C</gtr:id><gtr:title>Role of zinc-alpha2-glycoprotein in mitochondrial remodelling in adipose tissue: implications for fuel utilisation and energy balance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E015379/1</gtr:grantReference><gtr:abstractText>The regulation of body weight and body fat is complex and understanding the various processes involved is a major challenge in biology. Chemicals from the brain help to determine the amount of food that we eat and how the digested food energy is used in our daily activities. Surplus food energy in the form of lipid, is stored in a special organ called white adipose tissue, or white fat. Recently, the direct importance of white fat in the control of body weight has been firmly recognised. This is because the fat cells in adipose tissue, in addition to being the major site for lipid storage, can produce a wide range of protein factors that act locally and/or distantly to regulate body weight and different biological processes, including appetite and the use of food energy. Furthermore, the processing of lipid within fat cells has substantial effects on keeping food energy intake and expenditure in balance. Organelles inside cells called mitochondria are key players in how fat cells processes lipid, including how it is accumulated, broken-down and burnt off to provide energy. Changes in the number, structure and function of mitochondria in fat cells significantly affect total body fat mass and the sensitivity to the hormone insulin. Recent studies from our group have identified a specific molecule called Zinc-alpha2-glycoprotein (ZAG) as a new protein factor which is made by fat cells. We have also found that ZAG production in fat cells is inversely related to the amount of body fat, being higher in mice with little fat. Additional work in these mice indicates that alterations of mitochondrial amount and structure in fat cells is associated with an increase in the production of the proteins involved in how lipids are used. The aim of this project is to test our new idea that ZAG has a major role in how white fat functions, especially in the control of lipid use through altering the activity of the mitochondria within fat cells. To examine this idea, we will study to what extent ZAG modifies the use of lipid by analysing the effects of ZAG on the production of proteins, particularly those involved in the burning up lipids, in the fat cells. We will also examine whether ZAG can alter the amount and the structure of mitochondria in fat cells, and whether it modifies the capacity to use fuel in these cells. Overall, the findings from this research will help us to understand how the function of fat cells is controlled. Since the loss of the normal functioning of mitochondria in fat cells contributes to the development of obesity and diabetes, identification of the role of ZAG in the modulation of mitochondrial activity may have wider implications in human health. This could lead to a new target for the development of drugs for protecting against too much lipid accumulation in obesity and other metabolic disorders.</gtr:abstractText><gtr:technicalSummary>The importance of white adipose tissue in the control of energy balance is now firmly recognised. Adipocytes secrete a wide range of protein factors (adipokines) that regulate body weight, and adipocyte metabolism has profound effects on energy homeostasis. Mitochondria are key players in adipocyte metabolism and are involved in lipolysis, lipogenesis and fatty acid oxidation. Mitochondrial remodelling (changes in abundance, structure and function) in adipocytes significantly affects body fat accretion and insulin sensitivity. Recent work from our group has identified Zinc-alpha2-glycoprotein (ZAG) as a novel adipokine which may have a local action in adipose tissue to enhance lipid disposal by modulating mitochondrial activity. The overall aim of this proposal is to test the hypothesis that ZAG functions locally to stimulate lipid utilisation through mitochondrial remodelling in adipocytes. The main objectives are to: (i) examine whether ZAG induces transcriptional regulation of genes encoding mitochondrial proteins, particularly those involved in mitochondrial uncoupling, respiration, and fatty acid oxidation, employing 3T3-L1 adipocytes with Affymetrix DNA arrays; (ii) modulate the expression levels of ZAG in adipocytes using ZAG transfection or ZAG knock down with siRNA, to assess the effects on gene profiling of mitochondria with DNA arrays and the effects on key mitochondrial proteins by western blotting; (iii) establish whether ZAG alters the abundance and morphology of mitochondria in 3T3-L1 adipocytes and also in mouse adipose tissue, using fluorescence immunocytochemistry and transmission electron microscopy; (iv) identify whether ZAG stimulates mitochondrial respiration and fatty acid oxidation in 3T3-L1 cells with functional analysis including oxygen consumption and palmitate oxidation; (v) determine whether ZAG acts on AMPK signalling pathway leading to cellular events which facilitate the oxidative disposal of fatty acids in adipocytes.</gtr:technicalSummary><gtr:fund><gtr:end>2010-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>318927</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings have been desiminated to health workers and used by higher education and research institutions.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>4901E39E-BA93-40CB-A3E8-42B742FD13C0</gtr:id><gtr:impactTypes><gtr:impactType>Cultural</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54525631696b85.99491866</gtr:outcomeId><gtr:sector>Education,Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>ZAG is a novel adipokine which modulates body fat mass by stimulating lipid mobilization.</gtr:description><gtr:exploitationPathways>new research projects
pharmaceutical industry</gtr:exploitationPathways><gtr:id>6B74E3AF-EDB3-40AE-A7DC-D5DB224061FA</gtr:id><gtr:outcomeId>54525211952407.95506168</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A82521DB-D498-457B-AAA9-BB2531FC3592</gtr:id><gtr:title>Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-a2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study.</gtr:title><gtr:parentPublicationTitle>BMC anesthesiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae7b5b63068da85235959d08445e7f1"><gtr:id>fae7b5b63068da85235959d08445e7f1</gtr:id><gtr:otherNames>Welters ID</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2253</gtr:issn><gtr:outcomeId>56af7a5b741b65.10301460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C95D5542-B2E0-4929-AD91-CBF3E472D946</gtr:id><gtr:title>Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/245f49b97d48361c5409b32dbacf3153"><gtr:id>245f49b97d48361c5409b32dbacf3153</gtr:id><gtr:otherNames>Mracek T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pWjJ8L34UhN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>893C2564-2DBF-483C-91B3-E4D2B9083590</gtr:id><gtr:title>Downregulation of zinc-{alpha}2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-alpha in adipocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/245f49b97d48361c5409b32dbacf3153"><gtr:id>245f49b97d48361c5409b32dbacf3153</gtr:id><gtr:otherNames>Mracek T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>sDbSmAqntAu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>163202F9-532C-4466-99A0-0FEB4F28E12B</gtr:id><gtr:title>New insights into adipose tissue atrophy in cancer cachexia.</gtr:title><gtr:parentPublicationTitle>The Proceedings of the Nutrition Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d494ef038ece2fdbdd7b435e84033146"><gtr:id>d494ef038ece2fdbdd7b435e84033146</gtr:id><gtr:otherNames>Bing C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0029-6651</gtr:issn><gtr:outcomeId>2507FC70A26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CC67FEB-0A9B-477F-9C7E-064C26A5CFEC</gtr:id><gtr:title>Zinc-a2-glycoprotein: a proliferative factor for breast cancer? In vitro study and molecular mechanisms.</gtr:title><gtr:parentPublicationTitle>Oncology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3eb6c4ff007098931d3c1a97f80766f"><gtr:id>f3eb6c4ff007098931d3c1a97f80766f</gtr:id><gtr:otherNames>Delort L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1021-335X</gtr:issn><gtr:outcomeId>pm_12917_27_23446778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D199FB7A-E307-40A0-96FB-9BAC494A0A83</gtr:id><gtr:title>The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/245f49b97d48361c5409b32dbacf3153"><gtr:id>245f49b97d48361c5409b32dbacf3153</gtr:id><gtr:otherNames>Mracek T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>AFPikpKpg18</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BC1DD16-4503-4E09-8CD6-61D494023FF8</gtr:id><gtr:title>Caloric restriction increases adiponectin expression by adipose tissue and prevents the inhibitory effect of insulin on circulating adiponectin in rats.</gtr:title><gtr:parentPublicationTitle>The Journal of nutritional biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f496c4da37e1c542ce9825fd20f7c559"><gtr:id>f496c4da37e1c542ce9825fd20f7c559</gtr:id><gtr:otherNames>Ding Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0955-2863</gtr:issn><gtr:outcomeId>rkejiXUe9du</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E015379/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>